The medical treatment of Cushing's disease: Effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 1, 2009, Pages 223-230

  Pivonello, Rosario ^a,b   De Martino, Maria Cristina ^a   Cappabianca, Paolo ^a   De Leo, Monica ^a   Faggiano, Antongiulio ^a   Lombardi, Gaetano ^a   Hofland, Leo J ^b   Lamberts, Steven W J ^b   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CABERGOLINE; CALCIUM ANTAGONIST; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROCORTISONE; KETOCONAZOLE; METFORMIN;

ADULT; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CUSHING DISEASE; DIABETES MELLITUS; DIZZINESS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYDROCORTISONE URINE LEVEL; HYPERTENSION; HYPOTENSION; LONG TERM CARE; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SHORT COURSE THERAPY; STEROID EXCRETION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION;

EID: 58149389462     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1533     Document Type: Article

References (20)

1. Pivonello R, DeMartino MC, DeLeo M, Lombardi G, Colao A 2008 Cushing's syndrome. Endocrinol Metab Clin North Am 37:135-149
2. Newell-Price J, Bertagna X, Grossman AB, Nieman LK 2006 Cushing's syndrome. Lancet 367:1605-1617
3. Pivonello R, Faggiano A, Lombardi G, Colao A 2005 The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 34:327-339
4. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M 2008 Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454-2462
5. Miller JW, Crapo L 1993 The medical treatment of Cushing's syndrome. Endocr Rev 14:443-458
6. Lamberts SW, Klijn JG, De Quijada M, Timmermans HA, Uitterlinden P, De Jong FH, Birkenhager JC 1980 The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. J Clin Endocrinol Metab 51:307-311
7. Invitti C, De Martin M, Danesi L, Cavagnini F 1995 Effect of injectable bromocriptine in patients with Cushing's disease. Exp Clin Endocrinol Diabetes 103:266-271
8. Bevan JS, Webster J, Burke CW, Scanlon MF 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-240
9. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SWJ 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462
10. Lamberts SW, Birkenhager JC 1976 Bromocriptine in Nelson's syndrome and Cushing's disease. Lancet 2:811
11. Lamberts SW, Timmermans HA, De Jong FH, Birkenhager JC 1977 The role of dopaminergic depletion in the pathogenesis of Cushing's disease and the possible consequences for medical therapy. Clin Endocrinol (Oxf) 7:185-193
12. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A 1999 Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 22:860-865
13. Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C 2004 Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 62:300-305
14. Petrossians P, Ronci N, Valdes-Socin H, Kalife A, Stevenaert A, Bloch B, Tabarin A, Beckers A 2001 ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 144:51-57
15. Miyoshi T, Otsuka F, Takeda M, Inagaki K, Suzuki J, Ogura T, Date I, Hashimoto K, Makino H 2004 Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J Endocrinol Invest 27:1055-1059
16. Tsjoen G, Defeyter I, Van De Saffele J, Rubens R, Vandeweghe M 2002 Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline. J Endocrinol Invest 25:172-175
17. Murphy MB 2000 Dopamine: a role in the pathogenesis and treatment of hypertension. J Hum Hypertens 14(Suppl 1):S47-S50
18. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA 2000 Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23:1154-1161
19. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E 2007 Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38
20. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46